source
- Drug makers and patient groups call on FDA to suspend fast‑track voucher programThe FDA held a town‑hall listening session on its Commissioner’s National Priority Voucher program, hearing from 17 speakers that included patient advocates, pharmaceutical companies and academic r…
- Otsuka's Voyxact reduces kidney function decline in IgA nephropathy but falls short of expectations in Phase 3Otsuka reported Phase 3 trial results for its drug Voyxact in patients with IgA nephropathy, a chronic autoimmune kidney disease. In the study, patients receiving Voyxact experienced an annualized…